BMRN
BIOMARIN PHARMACEUTICAL INC
Nasdaq: BMRN · Novato, CA · Healthcare
$54.62-0.26 (-0.47%)Closed
Market Cap$10.50B
Cash$1.31Bmost recent
Runwayprofitable
P/E (TTM)30.3EPS $1.80
52-Wk Range$51.46 – $64.08
Avg Volume2.3M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$54.62-39.0%
Pipeline
Drug candidates sponsored by BIOMARIN PHARMACEUTICAL · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Naglazyme | Mucopolysaccharidosis VI+1 more | Completed | 2009-04past | 1 | |
| Phase 4 | Kuvan® | Phenylketonuria | Completed | 2023-01-04past | 2 | |
| Phase 4 | RDD to Palynziq | Phenylketonuria+1 more | Active, not recruiting | 2026-08 | 1 | |
| Phase 3 | N-acetylgalactosamine 4-sulfatase | Mucopolysaccharidosis VI | Completed | 2006-10past | 3 | |
| Phase 3 | BMN 110 Weekly | MPS IV A | Completed | 2012-08past | 1 | |
| Phase 3 | BMN 165 | Phenylketonuria | Completed | 2015-11-25past | 1 | |
| Phase 3 | BMN165 20mg/day | Phenylketonuria (PKU) | Completed | 2016-01-13past | 1 | |
| Phase 3 | BMN 110 - Weekly | Mucopolysaccharidosis IV A+2 more | Completed | 2016-06-16past | 1 | |
| Phase 3 | BMN 110 | Mucopolysaccharidosis IVA (Morquio A Syndrome)+4 more | Completed | 2016-07past | 7 | |
| Phase 3 | Drisapersen | Muscular Dystrophies+1 more | Terminated | 2016-09past | 3 | |
| Phase 3 | BMN 701 | Late-onset Pompe Disease+1 more | Completed | 2016-09-12past | 3 | |
| Phase 3 | sapropterin dihydrochloride | Phenylketonuria+2 more | Completed | 2018-09-14past | 8 | |
| Phase 3 | Vosoritide | Hypochondroplasia+1 more | Recruiting | 2026-08-01 | 3 | |
| Phase 3 | BMN 111 | Achondroplasia | Active, not recruiting | 2027-12 | 6 | |
| Phase 3 | Valoctocogene Roxaparvovec | Hemophilia A+6 more | Active, not recruiting | 2029-04 | 6 | |
| Phase 2 | BMN 333 | Achondroplasia | Not yet recruiting | 2029-06 | 1 | |
| Phase 3 | Pegvaliase | Phenylketonuria (PKU)+1 more | Recruiting | 2032-10-04 | 5 | |
| Phase 3 | Placebo | Mucopolysaccharidosis VI | Completed | — | 1 | |
| Phase 3 | sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | Phenylketonurias | Completed | — | 1 | |
| Phase 2 | 6R-BH4 (sapropterin dihydrochloride) | Hypertension | Completed | 2006-12past | 1 | |
| Phase 2 | Phenoptin | Tetrahydrobiopterin Deficiencies+1 more | Completed | 2009-06past | 1 | |
| Phase 1 | PRO044 SC | Duchenne Muscular Dystrophy | Completed | 2013-05past | 1 | |
| Phase 2 | BMN 165 (rAvPAL-PEG) | Phenylketonuria | Completed | 2013-09past | 1 | |
| Phase 2 | Sapropterin | Phenylketonuria | Terminated | 2014-11past | 1 | |
| Phase 2 | rAvPAL-PEG 0.001 mg/kg | Phenylketonuria | Completed | 2015-06past | 1 | |
| Phase 2 | PRO044 SC 6 mg/kg | Duchenne Muscular Dystrophy | Terminated | 2016-07-01past | 1 | |
| Phase 1 | Regimen Selection Phase Group 2 | Duchenne Muscular Dystrophy | Terminated | 2016-08-03past | 1 | |
| Phase 1 | PRO045, 0.15 mg/kg/week | Duchenne Muscular Dystrophy | Terminated | 2016-08-31past | 1 | |
| Phase 2 | BMN 044 IV 6 mg/kg | Duchenne Muscular Dystrophy | Terminated | 2016-09past | 1 | |
| Phase 2 | rAvPAL-PEG | Phenylketonuria | Completed | 2019-01-31past | 3 | |
| Phase 1 | BMN 190 | Jansky-Bielschowsky Disease+4 more | Completed | 2020-12-10past | 2 | |
| Phase 2 | BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1) | Jansky-Bielschowsky Disease+4 more | Completed | 2022-04-20past | 1 | |
| Phase 2 | Vosoritide Injection | Idiopathic Short Stature+3 more | Recruiting | 2026-06 | 2 | |
| Phase 1 | BMN 351 | Duchenne Muscular Dystrophy | Recruiting | 2026-09-30 | 1 | |
| Phase 1 | BMN 307 | Phenylketonuria (PKU) | Active, not recruiting | 2027-12 | 1 | |
| Phase 1 | Dose 1 of BMN 331 | Hereditary Angioedema+1 more | Active, not recruiting | 2028-11 | 1 | |
| Phase 2 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. | Achondroplasia | Active, not recruiting | 2038-05 | 1 | |
| Phase 1 | BMN 111 administration via vial and syringe | Achondroplasia | Terminated | 2023-06-14past | 1 | |
| Phase 1 | BMN 255 | Hyperoxaluria+2 more | Withdrawn | 2024-03-25past | 1 | |
| Phase 1 | BMN 349 | Alpha 1-Antitrypsin Deficiency | Recruiting | 2025-09past | 1 | |
| N/A | Unnamed | MPS IV A+2 more | Terminated | 2014-07past | 1 | |
| N/A | Unnamed | Late-onset Pompe Disease | Terminated | 2016-06-22past | 1 | |
| N/A | Unnamed | Duchenne Muscular Dystrophy | Terminated | 2016-10-01past | 1 | |
| N/A | Unnamed | Phenylketonuria | Completed | 2017-02-01past | 1 | |
| N/A | Unnamed | Phenylketonuria (PKU) | Completed | 2019-07-31past | 1 | |
| N/A | Unnamed | Achondroplasia | Completed | 2020-04-29past | 1 | |
| N/A | Unnamed | Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) | Completed | 2020-05-01past | 1 | |
| N/A | KUVAN | Tetrahydrobiopterin Deficiency+2 more | Completed | 2021-01-29past | 2 | |
| N/A | Unnamed | Achondroplasia | Completed | 2021-02past | 1 | |
| N/A | Unnamed | Achondroplasia | Completed | 2021-02-06past | 1 | |
| N/A | Unnamed | Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency | Completed | 2021-05-31past | 1 | |
| N/A | Unnamed | Phenylketonurias | Completed | 2022-06-02past | 1 | |
| N/A | Unnamed | Hemophilia A | Completed | 2023-09-20past | 1 | |
| N/A | Vimizim® (elosulfase alfa) | Mucopolysaccharidosis IV Type A+2 more | Completed | 2024-02-21past | 1 | |
| N/A | Cerliponase Alfa | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Active, not recruiting | 2030-08-31 | 1 | |
| N/A | Unnamed | Hemophilia A | Enrolling | 2040-01 | 1 | |
| N/A | Unnamed | Idiopathic Short Stature | Recruiting | 2040-12-31 | 1 | |
| N/A | Unnamed | Rare Genetic Disorders | Unknown | — | 1 | |
| N/A | BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1) | CLN2 Disease | Approved For Marketing | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for BMRN. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.